SIGLEC1 Antibody

What is SIGLEC1 and what are its key structural characteristics relevant to antibody selection?

SIGLEC1 (CD169, sialoadhesin) is a 175-185 kDa transmembrane glycoprotein belonging to the sialic acid-specific I-type lectin family within the immunoglobulin superfamily. Its structure consists of an extensive extracellular domain (ECD) spanning 1622 amino acids that includes one Ig-like V-set domain followed by 16 Ig-like C2-set domains, a 21 amino acid transmembrane segment, and a 44 amino acid cytoplasmic domain . The protein's adhesive functionality is primarily mediated by the N-terminal Ig-like domain, which exhibits selectivity for alpha 2,3-linked sialic acid residues .

When selecting antibodies, researchers should consider that human SIGLEC1 shares approximately 70% amino acid sequence identity with mouse and rat SIGLEC1 within the ECD. Additionally, alternate splicing can generate a potentially soluble form of the ECD and a second isoform with a substituted cytoplasmic domain . The sialylated and sulfated N-linked carbohydrates that modify SIGLEC1 itself are required for proper ligand binding, which may affect epitope availability for certain antibodies .

For optimal antibody selection, consider targeting conserved epitopes if cross-species reactivity is desired, or species-specific regions for selective detection. The large size and extensive glycosylation of SIGLEC1 may influence antibody accessibility to certain epitopes under different experimental conditions.

How does SIGLEC1 expression vary across cell types and disease states, and what implications does this have for experimental design?

SIGLEC1 expression exhibits distinct cell-type specificity and disease-associated patterns that researchers must consider when designing experiments. Under normal conditions, SIGLEC1 expression is predominantly restricted to lymph node and splenic macrophages, plus some tissue macrophages . This specific distribution makes it a valuable marker for certain macrophage populations.

In disease states, SIGLEC1 expression patterns change significantly. It is induced on circulating monocytes during systemic sclerosis and HIV-1 infection . SIGLEC1 is also expressed on dendritic cells following rhinovirus exposure, and these dendritic cells have been shown to promote T cell anergy . In pregnancy, increased SIGLEC1 expression on monocytes has been associated with congenital heart block .

For robust experimental design, researchers should:

• Include appropriate cell type controls when studying SIGLEC1 expression

• Account for disease-specific expression patterns that may alter baseline levels

• Consider timing of sample collection, as SIGLEC1 expression can be dynamically regulated

• Utilize complementary detection methods (flow cytometry, immunoblotting, immunoassays) to confirm expression patterns

• Normalize expression data to appropriate housekeeping genes or proteins when making comparisons across different conditions

Understanding these expression patterns is crucial for interpreting experimental results, particularly when using SIGLEC1 as a biomarker or studying its role in disease processes.

What criteria should guide the selection of SIGLEC1 antibodies for different experimental applications, and how do these affect results interpretation?

Selecting appropriate SIGLEC1 antibodies requires careful consideration of application-specific criteria to ensure experimental success and accurate interpretation of results.

For Western blotting applications, antibodies recognizing denatured epitopes are preferred. The search results indicate that anti-human SIGLEC1 antibodies can detect a specific band at approximately 180-200 kDa in lysates of SH-SY5Y human neuroblastoma cell line and human lymph node under reducing conditions . For Western blotting of rat SIGLEC1, antibodies like CAB22677 have been validated at dilutions of 1:500 to 1:1000 .

For flow cytometry, antibodies that recognize native conformational epitopes are essential. Flow cytometric detection of SIGLEC1 expression on CD14+ monocytes has been successfully performed using fluorochrome-conjugated antibodies against SIGLEC1 (Clone 7-239) . This application is particularly valuable for analyzing SIGLEC1 expression on specific cell populations in mixed samples.

For immunoassays measuring soluble SIGLEC1 (sSIGLEC1), a combination of capture and detection antibodies with non-overlapping epitopes is required. A non-isotopic time-resolved fluorescence assay using mouse monoclonal anti-human SIGLEC1 as capture antibody (AB18619) and biotinylated sheep polyclonal detection antibody (BAF5197) has been successfully employed .

For functional studies, neutralizing antibodies that block SIGLEC1 interactions are valuable. The neutralization dose (ND50) for sheep anti-human SIGLEC1 antibody is typically 1.5-7.5 μg/mL in the presence of 5 μg/mL recombinant human SIGLEC1 Fc chimera .

When interpreting results, researchers should consider:

• The specific epitope(s) recognized by the antibody

• Potential cross-reactivity with related Siglec family members

• The effect of sample preparation on epitope availability

• The need for appropriate positive and negative controls

• The impact of species differences on antibody reactivity

• Batch-to-batch variation that may affect antibody performance

How can soluble SIGLEC1 (sSIGLEC1) be effectively measured and utilized as a biomarker in autoimmune and inflammatory conditions?

Soluble SIGLEC1 (sSIGLEC1) has emerged as a promising biomarker for type I interferon activity in systemic autoimmune, inflammatory, and infectious diseases. Researchers have developed specific methodologies to accurately measure sSIGLEC1 in plasma/serum samples.

A robust immunoassay approach utilizes a non-isotopic time-resolved fluorescence (TRF) assay based on dissociation-enhanced lanthanide fluorescent immunoassay technology (DELFIA) . This method employs:

• Mouse monoclonal anti-human SIGLEC1 as a capture antibody (1 μg/ml)

• Biotinylated sheep polyclonal detection antibody (200 ng/ml)

• Dilution of plasma/serum samples 1:10 in assay buffer

• Overnight incubation at 4°C following 2-hour room temperature incubation

This assay provides several advantages over cell-based SIGLEC1 detection methods:

• Requires only small volumes of plasma/serum

• Does not need intact cells or flow cytometry

• Suitable for high-throughput screening

• Cost-effective for large-scale studies

Clinical studies have revealed significant associations between sSIGLEC1 levels and disease parameters. In SLE patients, plasma sSIGLEC1 concentrations strongly correlate with:

• SIGLEC1 expression on blood monocyte surfaces

• Type I interferon-regulated gene (IRG) expression

• Lower serum complement component 3 levels (in European patients)

• Increased frequency of renal complications (in European patients)

Notably, ancestry-related differences in sSIGLEC1 concentrations have been observed, with non-European ancestry SLE patients showing higher levels compared to those of European ancestry . This highlights the importance of considering demographic factors when interpreting sSIGLEC1 measurements.

For effective biomarker utilization, researchers should:

• Establish appropriate reference ranges based on population characteristics

• Consider ancestry as a potential confounding factor

• Use sSIGLEC1 in conjunction with other established biomarkers

• Apply sSIGLEC1 measurement for patient stratification in clinical trials, particularly those involving drugs modulating interferon signaling pathways

What roles does SIGLEC1 play in viral infections, and how can antibodies help elucidate these mechanisms?

SIGLEC1 has significant roles in viral infection processes, particularly in HIV-1 infection, where it can trap viral particles . SIGLEC1 antibodies are crucial tools for investigating these mechanisms through various experimental approaches.

In HIV-1 research, antibodies against SIGLEC1 have revealed that the protein's induction on circulating monocytes during infection may contribute to viral pathogenesis . Researchers can use neutralizing antibodies to block SIGLEC1-mediated viral particle capture and transfer, helping to elucidate the specific contribution of this protein to viral dissemination.

For studying viral entry and trafficking, SIGLEC1 antibodies can be employed in:

• Immunofluorescence microscopy to visualize viral particle colocalization with SIGLEC1

• Immunoprecipitation experiments to identify viral components interacting with SIGLEC1

• Flow cytometry to quantify SIGLEC1 expression changes during viral infection

• Functional blocking studies to determine the impact of SIGLEC1-virus interactions on infection outcomes

When researching the role of SIGLEC1 in antiviral immune responses, antibodies can help:

• Identify SIGLEC1-expressing cells responding to viral infection

• Characterize the phenotype and function of these cells through multi-parameter flow cytometry

• Track changes in SIGLEC1 expression following exposure to different viral pathogens

• Assess the impact of SIGLEC1 blockade on antigen presentation and T cell activation

For effective research in this area, use specific experimental controls:

• Isotype controls to account for non-specific antibody binding

• Genetic knockdown or knockout systems to confirm antibody specificity

• Dose-response studies with blocking antibodies to determine optimal concentrations

• Time-course experiments to capture the dynamics of SIGLEC1 expression during infection

What are the optimal conditions for detecting SIGLEC1 via Western blot, and how should results be interpreted?

Detecting SIGLEC1 via Western blot requires careful optimization due to its high molecular weight (175-185 kDa) and glycosylation patterns. Based on the search results, the following technical considerations are crucial for successful detection and interpretation:

Sample Preparation:

• Reducing conditions are recommended for SIGLEC1 detection

• Use appropriate buffer systems such as Western Blot Buffer Group 1

• Include protease inhibitors to prevent degradation of the high molecular weight protein

• Consider phosphatase inhibitors if studying post-translational modifications

Gel Electrophoresis Parameters:

• Utilize low percentage gels (6-8%) to facilitate separation of high molecular weight proteins

• Extend running time to achieve better resolution in the high molecular weight range

• Consider gradient gels (4-15%) for simultaneous analysis of SIGLEC1 and lower molecular weight proteins

Antibody Selection and Dilution:

• For human SIGLEC1 detection, Sheep Anti-Human SIGLEC1 Antigen Affinity-purified Polyclonal Antibody (AF5197) has been validated at 0.5 μg/mL concentration

• For rat SIGLEC1, Rabbit Polyclonal Antibody (CAB22677) has been validated at dilutions of 1:500 to 1:1000

• Secondary antibody selection should match the host species of the primary antibody (e.g., HRP-conjugated Anti-Sheep IgG for AF5197)

Expected Results and Interpretation:

• Human SIGLEC1 appears as a specific band at approximately 180-200 kDa

• Verify band specificity using appropriate positive controls (e.g., SH-SY5Y human neuroblastoma cell line and human lymph node for human SIGLEC1; rat spleen for rat SIGLEC1)

• Multiple bands may indicate glycosylation variants, proteolytic processing, or alternative splicing

• Absence of expected bands in positive control samples may suggest technical issues with transfer or detection

• Non-specific bands can be minimized by optimizing blocking conditions and antibody dilutions

Troubleshooting Recommendations:

• If weak signal is observed, consider longer exposure times or increased antibody concentration

• For high background, increase blocking time or washing steps

• If multiple non-specific bands appear, try more stringent washing conditions or higher antibody dilutions

• For inconsistent results, verify protein loading using housekeeping protein controls

By following these technical considerations, researchers can achieve reliable and reproducible detection of SIGLEC1 via Western blot, facilitating accurate interpretation of experimental results.

What is the relationship between membrane-bound and soluble SIGLEC1, and how does this impact experimental design choices?

The relationship between membrane-bound SIGLEC1 on monocytes and soluble SIGLEC1 (sSIGLEC1) in plasma/serum is a critical consideration for researchers designing SIGLEC1-focused experiments. Evidence indicates a strong correlation between these two forms, suggesting they may reflect similar biological processes.

Studies have demonstrated that plasma concentrations of sSIGLEC1 strongly correlate with expression of SIGLEC1 on the surface of blood monocytes in SLE patients . This correlation provides researchers with flexible options for experimental design, as either measurement might serve as an indicator of type I interferon activity.

When deciding which form to measure, consider these experimental factors:

For longitudinal studies or clinical trials where repeated measurements are necessary, sSIGLEC1 offers practical advantages due to:

• Simplified sample collection and storage

• Reduced technical variability

• Cost-effectiveness for large sample numbers

• Compatibility with retrospective studies using banked samples

• Cell-specific expression patterns

• Potential for multi-parameter analysis with other cellular markers

• Direct assessment of the protein in its functional membrane-bound form

The mechanistic basis for this correlation likely involves alternate splicing that generates a soluble form of the extracellular domain, as mentioned in the search results . Additionally, proteolytic shedding of membrane-bound SIGLEC1 may contribute to sSIGLEC1 levels, though this mechanism requires further investigation.

For comprehensive studies, researchers might consider measuring both forms in a subset of samples to establish correlation within their specific experimental system before selecting one approach for larger-scale analyses.

How can SIGLEC1 antibodies be used to investigate type I interferon signatures in autoimmune diseases?

SIGLEC1 serves as a valuable cell-type specific biomarker for type I interferon activity in autoimmune diseases, particularly systemic lupus erythematosus (SLE). Researchers can utilize SIGLEC1 antibodies through multiple approaches to investigate interferon signatures.

The relationship between SIGLEC1 and type I interferon is well-established, with studies demonstrating strong correlation between sSIGLEC1 concentrations and interferon-regulated gene (IRG) expression in SLE patients . This correlation positions SIGLEC1 as an efficient proxy for assessing type I interferon activity.

Flow Cytometry Approach:

Researchers can quantify SIGLEC1 expression on monocyte surfaces using flow cytometry with these methodological considerations:

• Isolate PBMCs from patient samples

• Immunostain with fluorochrome-conjugated antibodies against CD14 (monocyte marker) and SIGLEC1

• Analyze SIGLEC1 expression specifically on CD14+ monocytes

• Include viability dye to exclude dead cells

• Compare expression levels between patients and healthy controls or across disease states

The search results describe this approach using anti-CD14 (Clone M5E2) and anti-SIGLEC1 (Clone 7-239) antibodies .

Immunoassay for Soluble SIGLEC1:

For high-throughput analysis or when intact cells are unavailable, researchers can measure sSIGLEC1 using immunoassay techniques:

• Employ a sandwich immunoassay format with mouse monoclonal anti-human SIGLEC1 capture antibody

• Detect bound sSIGLEC1 using biotinylated sheep polyclonal detection antibody

• Dilute plasma/serum samples 1:10 in appropriate assay buffer

• Include standard curves for quantification

• Correlate results with clinical parameters or other interferon markers

This approach allows assessment of interferon activity in large cohorts or longitudinal studies with minimal sample volume requirements .

Clinical Applications:

When investigating interferon signatures in autoimmune diseases, researchers should consider:

• Stratifying patients based on SIGLEC1 expression for clinical trials targeting interferon pathways

• Using SIGLEC1 as a secondary endpoint to assess treatment efficacy

• Exploring ancestry-related differences in SIGLEC1 expression

• Correlating SIGLEC1 levels with specific disease manifestations (e.g., renal complications in SLE)

• Monitoring SIGLEC1 longitudinally to track disease progression or treatment response

The search results indicate that sSIGLEC1 concentrations are associated with ancestry, complement component 3 levels, and renal complications in SLE patients, providing valuable clinical correlations for research design .

By implementing these antibody-based approaches, researchers can comprehensively investigate type I interferon signatures in autoimmune diseases, potentially leading to improved patient stratification and therapeutic strategies.

What validation strategies should be employed to ensure SIGLEC1 antibody specificity and performance across different research applications?

Rigorous validation of SIGLEC1 antibodies is essential to ensure experimental reliability and reproducibility. Researchers should implement comprehensive validation strategies tailored to their specific applications.

Western Blot Validation:

• Positive control verification: Confirm antibody detection using known SIGLEC1-expressing samples:

  • Human: SH-SY5Y neuroblastoma cell line and human lymph node

  • Rat: Spleen tissue

• Molecular weight confirmation: Verify detection at the expected molecular weight (180-200 kDa for human SIGLEC1)

• Knockdown/knockout controls: Compare antibody reactivity in SIGLEC1-depleted vs. normal samples

• Cross-reactivity assessment: Test against related Siglec family members to confirm specificity

• Antibody titration: Determine optimal concentration ranges (e.g., 0.5 μg/mL for AF5197 antibody)

Flow Cytometry Validation:

• Fluorophore selection: Ensure fluorophore conjugation does not affect antibody binding properties

• Titration experiments: Determine optimal antibody concentration to maximize signal-to-noise ratio

• Blocking experiments: Confirm specificity through competitive binding with unlabeled antibody

• FMO (Fluorescence Minus One) controls: Assess spectral overlap and compensation requirements

• Isotype controls: Account for non-specific binding

Immunoassay Validation:

• Antibody pair optimization: Test multiple capture and detection antibody combinations

• Standard curve linearity: Verify detection across a physiologically relevant concentration range

• Spike-and-recovery experiments: Assess matrix effects from plasma/serum components

• Precision assessment: Determine intra- and inter-assay coefficients of variation

• Reference sample inclusion: Maintain consistent controls across experiments

Functional Validation:

• Neutralization assays: Confirm blocking activity using cell adhesion assays

  • Example: The ND50 for anti-human SIGLEC1 antibody (AF5197) is typically 1.5-7.5 μg/mL

• Epitope mapping: Identify the specific binding regions to predict potential functional effects

• Species cross-reactivity: Determine reactivity across species if conducting comparative studies

• Activity in relevant biological contexts: Verify antibody performance in disease-specific models

Documentation and Reporting:

Researchers should thoroughly document validation results, including:

• Antibody source, catalog number, and lot information

• Detailed experimental protocols

• Positive and negative control results

• Known limitations or constraints

• Application-specific optimization parameters

By implementing these comprehensive validation strategies, researchers can ensure that SIGLEC1 antibodies deliver reliable, reproducible results across different experimental applications and biological systems.

How does SIGLEC1 contribute to disease pathogenesis in autoimmune conditions, and what methodologies can best elucidate these mechanisms?

SIGLEC1 plays significant roles in autoimmune disease pathogenesis, particularly through its involvement in type I interferon pathways and antigen presentation. Understanding these contributions requires specialized methodological approaches using SIGLEC1 antibodies and related techniques.

In systemic lupus erythematosus (SLE), elevated SIGLEC1 expression correlates with type I interferon-regulated gene expression and specific clinical manifestations . Importantly, ancestry-related differences in sSIGLEC1 concentrations have been observed, with non-European ancestry patients showing higher levels than those of European ancestry . This suggests potential genetic or environmental factors influencing SIGLEC1 regulation in different populations.

Higher sSIGLEC1 concentrations in European SLE patients associate with:

• Lower serum complement component 3 levels

• Increased frequency of renal complications

These associations indicate SIGLEC1's potential role in disease severity and organ-specific manifestations.

Methodological Approaches for Investigating SIGLEC1 in Disease:

• Gene Expression Analysis:

  • Quantitative PCR to measure SIGLEC1 mRNA levels

  • RNA sequencing to identify co-expressed genes in disease states

  • Single-cell RNA sequencing to determine cell-specific expression patterns

• Protein Detection Methods:

  • Flow cytometry to quantify cell surface expression on specific immune cell subsets

  • Immunohistochemistry to visualize tissue distribution in affected organs

  • sSIGLEC1 immunoassays to measure systemic levels

• Functional Studies:

  • Antibody neutralization experiments to block SIGLEC1-mediated interactions

  • Cell adhesion assays to assess SIGLEC1 binding to sialylated ligands

  • Antigen presentation assays to evaluate effects on T cell activation

• Disease Correlation Studies:

  • Longitudinal monitoring of SIGLEC1 levels during disease flares and remission

  • Correlation with established disease activity scores

  • Assessment of SIGLEC1 expression changes following therapeutic interventions

• Mechanistic Investigations:

  • CRISPR/Cas9-mediated knockout models to determine causal relationships

  • Co-immunoprecipitation to identify interaction partners

  • Intracellular trafficking studies to track SIGLEC1 localization in disease states

For comprehensive analysis of SIGLEC1's role in disease pathogenesis, researchers should consider multimodal approaches combining these methodologies. The strong correlation between soluble and membrane-bound SIGLEC1 provides flexibility in experimental design, allowing researchers to select the most appropriate measurement approach based on their specific research questions and available resources .